Crossmark

Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12890-020-01224-5

Published Online: 2020-07-11

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Corral, Mitra

DeYoung, Kathryn

Kong, Amanda M.
Funding

Funding for this research was provided by:

Genentech (N/A)
License Information

Text and Data Mining valid from 2020-07-11

Version of Record valid from 2020-07-11
More Information

Article History

Received: 9 January 2020

Accepted: 2 July 2020

First Online: 11 July 2020

Ethics approval and consent to participate

: All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). The databases used in the study are fully de-identified and compliant with the HIPAA. Research using the MarketScan Research Databases falls under Title 45 of the Code of Federal Regulations Part 46.101(b)(4) exemption from Institutional Review Board review because the databases contain only information that cannot be used to identify study subjects. As the data were de-identified, consent from patients was not sought.

: Not applicable.

: MC is employed by Genentech, Inc. AMK and KD are employed by IBM Watson Health and received funding from Genentech, Inc. to conduct this study.

Document is current

Any future updates will be listed below